A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

Employers have the opportunity to lead by example: to stop treating obesity as invisible and start addressing it as the ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

The first time around, 59-year-old James Brown lost a stone and a half when he took medication that aids weight loss. This ...

Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...

Weight loss injections work by making you feel fuller and less hungry. There are plenty of weight loss medication options to ...

Unions blame ‘greed’ by healthcare providers, state officials say pricey weight-loss meds and increasing demand for care are ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...